eLaws | eCases | United States Code | Federal Courts |

National Brain Tumor Society - Comment

Document ID: FDA-2012-D-0432-0011
Document Type: Public Submission
Agency: Food And Drug Administration
Received Date: July 30 2012, at 12:00 AM Eastern Daylight Time
Date Posted: August 7 2012, at 12:00 AM Eastern Standard Time
Comment Start Date: May 30 2012, at 12:00 AM Eastern Standard Time
Comment Due Date: July 30 2012, at 11:59 PM Eastern Standard Time
Tracking Number: 810b9253
View Document:

This is comment on Notice

Draft Guidance for Industry on Pathologic Complete Response in Neoadjuvant Treatment of High-Risk Early-Stage Breast Cancer: Use as an Endpoint to Support Accelerated Approval

View Comment

Please see the attached file for comments pertaining to the draft guidance on behalf of the National Brain Tumor Society.

Attachments:

NBTS Comments to Guidance 2012

Title:
NBTS Comments to Guidance 2012

View Attachment:

View as format pdf

Related Comments

View All

Total: 12

AstraZeneca - Comment
Public Submission Posted: 07/23/2012 ID: FDA-2012-D-0432-0003

Comment Period Closed
Jul 30,2012 11:59 PM ET

Steve Jones - Comment
Public Submission Posted: 08/07/2012 ID: FDA-2012-D-0432-0007

Comment Period Closed
Jul 30,2012 11:59 PM ET

Genentech - Comment
Public Submission Posted: 08/07/2012 ID: FDA-2012-D-0432-0008

Comment Period Closed
Jul 30,2012 11:59 PM ET

Biotechnology Industry Organization (BIO) - Comment
Public Submission Posted: 08/07/2012 ID: FDA-2012-D-0432-0010

Comment Period Closed
Jul 30,2012 11:59 PM ET

National Brain Tumor Society - Comment
Public Submission Posted: 08/07/2012 ID: FDA-2012-D-0432-0011

Comment Period Closed
Jul 30,2012 11:59 PM ET